SomnoMed (ASX:SOM): Leadership Reset and Virtus Product Launch Outlook

Aditi Sarkar

14 August 2026 12:30 PM AEST

SomnoMed (ASX:SOM): Leadership Reset and Virtus Product Launch Outlook

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

SomnoMed (ASX:SOM) appointed Karen Borg as sole chief executive following the departure of Co-CEO Amrita Blickstead.
FY26 preliminary Revenue is expected below previous guidance due to European market conditions and currency impacts.
Virtus expands SomnoMed’s oral appliance portfolio for patients with obstructive sleep apnoea and sleep bruxism.
FY27 priorities include controlled growth, product adoption and stabilising market access.

SomnoMed (ASX:SOM) has entered a new phase following a Leadership transition, the launch of Virtus and a revised FY26 revenue outlook.

The company is moving towards a single-leadership structure under Karen Borg while managing near-term challenges in Europe and currency impacts on reported revenue.

The next phase will focus on commercial execution, product adoption and whether the Business can return to its targeted growth profile.

What Happened?

On 27 July 2026, SomnoMed announced that Karen Borg would become sole chief executive following the departure of Co-CEO and Executive Director Amrita Blickstead.

The company also appointed Greg Knight, previously Chief Transformation Officer, as Chief Operating Officer with responsibility for manufacturing, regulatory affairs, quality assurance, Research and Development and strategy.

Alongside the leadership update, SomnoMed advised that preliminary FY26 revenue would be below previous guidance due to European market conditions and currency movements.

The company also announced the market introduction of Virtus, an oral appliance designed for patients with obstructive sleep apnoea (OSA) and sleep bruxism.

Why It Matters

The move to a single chief executive structure provides clearer accountability for strategic execution.

The appointment of Borg as sole CEO and expanded operational responsibilities for Knight indicate a focus on simplifying decision-making and improving operational execution.

Virtus expands SomnoMed’s product offering into a specific patient segment where traditional oral appliances may face durability challenges due to teeth grinding.

SomnoMed has highlighted that approximately half of adults with obstructive sleep apnoea may also experience bruxism, creating a potential opportunity within its existing customer base.

The revenue shortfall also highlights the impact of European reimbursement changes and currency movements on the company’s reported performance.

The Numbers

SomnoMed expects preliminary unaudited FY26 revenue of approximately A$114 million to A$115 million.

This compares with previous guidance of A$119 million to A$126 million.

Despite the revenue shortfall, EBITDA is expected towards the middle of the company’s previous guidance range of A$10 million to A$12 million.

Management attributed the revenue impact to European market conditions and an appreciating Australian dollar, which strengthened by approximately 600 basis points in the second half.

Around 95% of SomnoMed’s revenue is generated in currencies outside Australia.

The company reported approximately A$17.2 million in cash, including around A$16.8 million in net cash.

SomnoMed has stated that it treats more than one million patients across more than 20 countries.

The Bigger Picture

SomnoMed operates within the oral appliance segment of the obstructive sleep apnoea market, providing an alternative to continuous positive airway pressure (CPAP) therapy.

The company’s long-term strategy is based on increasing adoption of oral appliance solutions among patients who seek alternatives to traditional mask-based treatments.

Virtus extends the product portfolio by targeting patients with both OSA and sleep bruxism.

The device received US 510(k) clearance for adults with mild-to-moderate obstructive sleep apnoea and snoring.

SomnoMed commenced controlled market release activities across North America, Europe and Asia-Pacific.

The European market remains a key focus area, with reimbursement and referral changes affecting patient access.

The Bull Case

The positive case for SomnoMed (ASX:SOM) is based on its established global patient base, product expansion and ability to maintain operating margins.

Virtus provides an additional product opportunity within the existing oral appliance market by addressing patients with combined OSA and bruxism needs.

The company’s EBITDA outlook indicates that cost management has supported profitability despite revenue pressure.

A recovery in European access conditions combined with Virtus adoption could support future revenue growth.

Risks Investors Should Understand

SomnoMed (ASX:SOM)’s business faces risks including currency exposure, reimbursement changes, product adoption uncertainty and execution challenges.

With approximately 95% of revenue generated offshore, Australian dollar movements can affect reported financial results.

European reimbursement and referral changes may continue to influence patient access and demand.

The Virtus launch requires clinician adoption and market acceptance, which may take time to develop.

Leadership transition also introduces execution considerations, while FY27 growth and margin expectations remain targets rather than guaranteed outcomes.

What Comes Next?

The next major milestone is SomnoMed’s FY26 audited results, expected around 28 August 2026.

Investors will monitor final financial results, FY27 outlook commentary, Virtus adoption trends and progress in stabilising European market conditions.

The company has indicated an objective of high single-digit revenue growth in FY27 while maintaining EBITDA margins consistent with FY26 levels.

Conclusion

SomnoMed (ASX:SOM) is entering a new stage with a simplified leadership structure, a new product launch and a revised financial outlook.

The company continues to benefit from its established global patient base and oral appliance expertise, while Virtus provides an additional product opportunity.

However, the near-term focus remains on addressing European market challenges, managing currency impacts and converting Virtus adoption into revenue growth. The upcoming FY26 results will provide further insight into the company’s next phase.

FAQs

Q: What is Virtus?

A:Virtus is SomnoMed’s oral appliance designed for patients with obstructive sleep apnoea and sleep bruxism.

Q: Who is leading SomnoMed now?

A:Karen Borg became SomnoMed’s sole chief executive following the departure of Co-CEO Amrita Blickstead.

Q: What was SomnoMed’s FY26 revenue outlook?

A:SomnoMed expects preliminary FY26 revenue of approximately A$114 million to A$115 million.

Q: What market does SomnoMed operate in?

A:SomnoMed develops oral appliance therapies for obstructive sleep apnoea patients.

Q: What are the key risks for SomnoMed?

A:Key risks include currency movements, reimbursement changes, product adoption and execution of growth plans.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.